The Royal London Hospital, Whitechapel_Investigational Site Number :8260006
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schmierer, Klaus
ChariotMS, NCT04695080 / 2018-005038-39: - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

Recruiting
2/3
200
Europe
Cladribine (MAVENCLAD®), Placebo
Queen Mary University of London, National Institute for Health Research, United Kingdom, Merck Serono Limited, UK, Multiple Sclerosis Society of Great Britain & Northern Ireland, National Multiple Sclerosis Society, Barts & The London NHS Trust
Advanced Multiple Sclerosis, Progressive Multiple Sclerosis
12/24
12/27
NCT05418010: Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Recruiting
2
40
Europe
Tysabri Injectable Product, Natalizumab, Placebo
Queen Mary University of London, Biogen, UCL Queen Square Institute of Neurology, Moorfields Eye Hospital NHS Foundation Trust, Barts & The London NHS Trust
Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination
05/24
05/24
DECISIve, NCT04024969: DiagnosE Using the Central veIn SIgn

Recruiting
N/A
115
Europe
T2* MRI, Lumbar puncture to test for presence of unmatched oligoclonal bands
Nottingham University Hospitals NHS Trust
Multiple Sclerosis
05/22
11/22
Porin, Lee
No trials found

Download Options